Skip to main content

Table 2 Comparison of demographic and clinical data of patients by PRD

From: Psychosocial and economic impact of rheumatic diseases on caregivers of Mexican children

  Total
200
n (%)
JIA
109
n (%)
JDM
28
n (%)
JSLE
63
n (%)
P value*
Age in years, median (IQR) 13 (10–15) 12 (9–15) 11 (8.2–13.7) 14.5 (12–16) 0.01**
Female 134 (67) 66 (60.6) 19 (67.9) 49 (77.8) 0.14
JIA category ERA NA 6 (5.5) NA NA NA
Oligoarticular 8 (7.3)
Polyarticular 66 (60.6)
Psoriatic 1 (0.9)
Systemic 16 (14.7)
Undifferentiated 12 (11)
Cutaneous symptoms 82/193 (42.5) 15 (13.8) 28 (100) 39/56 (69.6) <  0.001
Musculoskeletal symptoms a 161/193 (83.4) 109 (100) 27 (96.4) 25/56 (44.6) <  0.001
Systemic symptoms b 62/193 (32.1) 11 (10.1) 4 (14.3) 47/56 (83.9) <  0.001
Treatment NSAID 80/179 (44.7) 61/97 (62.9) 5/27 (18.5) 14/55 (25.5) <  0.001
DMARD 168/179 (93.9) 90/97 (92.8) 26/27 (96.3) 52/55 (94.5) 0.77
GC 82/179 (45.8) 18/97 (18.6) 25/27 (92.6) 39/55 (70.9) <  0.001
bDMARD 53/179 (29.6) 49/97 (50.5) 1/27 (3.7) 3/55 (5.5) <  0.001
Hospitalization 97/174 (55.7) 29/93 (31.2) 23/26 (88.5) 45/55 (81.8) <  0.001
Disability 43/174 (24.7) 19/93 (20.4) 16/26 (61.5) 8/55 (14.5) <  0.001
Active Disease 87/174 (50) 34/93 (36.6) 20/26 (76.9) 33/55 (60) <  0.001
  1. PRD Pediatric Rheumatic Disease, IQR Interquartile range, NA Does not apply, ERA Enthesitis related to Arthritis, NSAID Nonsteroidal anti-inflammatory drugs, DMARD Disease-modifying antirheumatic drugs, GC Systemic Glucocorticoids, bDMARD Biological therapy, JIA Juvenile Idiopathic Arthritis, JSLE Juvenile Systemic Lupus Erythematosus, JDM Juvenile Dermatomyositis
  2. a: Includes arthritis and myositis
  3. b: Includes neurological, hematological, pulmonary, gastrointestinal, cardiovascular, nephritis, serositis, adenomegaly, hepatomegaly, hepatitis, thyroiditis and uveitis manifestations
  4. * Analyzed with Chi square test
  5. ** Analyzed with Kruskal-Wallis test